Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2

You may also be interested in...



Advantage Sun Pharma As Tel Aviv Court Rules Out Special Tender Offer For Taro Shares

MUMBAI - Sun Pharmaceutical has emerged victorious in the protracted battle with Taro Pharmaceutical in its bid to acquire control of the Israel headquartered company. A Tel Aviv District Court rejected Taro's contention for a special tender offer under Israeli law before Sun Pharma could proceed with its objective to gain control of Taro management

Advantage Sun Pharma As Tel Aviv Court Rules Out Special Tender Offer For Taro Shares

MUMBAI - Sun Pharmaceutical has emerged victorious in the protracted battle with Taro Pharmaceutical in its bid to acquire control of the Israel headquartered company. A Tel Aviv District Court rejected Taro's contention for a special tender offer under Israeli law before Sun Pharma could proceed with its objective to gain control of Taro management

War Of Words Back Between Taro, Sun Pharma; Both Vow to Wrest Taro Control

MUMBAI - The battle for control of Israeli generic drug maker Taro is set to heat up further as Indian drug maker Sun Pharmaceuticals and Taro separately vowed their resolve to retain and acquire control of the beleaguered company

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel